Literature DB >> 12001045

Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines.

Anne Karin Brigtsen1, Dennis L Kasper, Carol J Baker, Harold J Jennings, Hilde-Kari Guttormsen.   

Abstract

Types Ia and Ib group B streptococcal (GBS) capsular polysaccharides (PSs) are structural isomers but are antigenically distinct. Immunization of healthy adults with GBS type Ia PS-tetanus toxoid (Ia-TT) or Ib-TT glycoconjugate vaccines induced > or = 4-fold increases in specific immunoglobulin G to the heterologous PS in more than two-thirds of subjects. Ib-TT vaccine-induced IgG bound with substantially higher affinity to homologous (Ib) than to heterologous (Ia) PS and promoted opsonophagocytic killing of GBS type Ib but not type Ia organisms. The failure of the Ib-TT- and Ia-TT-induced human antibodies to kill bacteria of the cross-reactive serotype contrasts with the results of previous studies in animals. Inhibition enzyme-linked immunosorbent assays demonstrated that Ib-TT-induced IgG to the homologous PS bound mainly to native Ib PS, whereas the cross-reactive antibodies recognized both native and derivative PSs. These results indicate that GBS Ia and Ib PSs should be included in a multivalent conjugate vaccine to prevent GBS disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12001045     DOI: 10.1086/340324

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Antibody-mediated complement C3b/iC3b binding to group B Streptococcus in paired mother and baby serum samples in a refugee population on the Thailand-Myanmar border.

Authors:  Jenny Herbert; Stephen Thomas; Charlotte Brookes; Claudia Turner; Paul Turner; Francois Nosten; Kirsty Le Doare; Michael Hudson; Paul T Heath; Andrew Gorringe; Stephen Taylor
Journal:  Clin Vaccine Immunol       Date:  2015-01-14

Review 2.  Group B Streptococcus: global incidence and vaccine development.

Authors:  Atul Kumar Johri; Lawrence C Paoletti; Philippe Glaser; Meenakshi Dua; Puja Kumari Sharma; Guido Grandi; Rino Rappuoli
Journal:  Nat Rev Microbiol       Date:  2006-11-06       Impact factor: 60.633

3.  Phagocytosis and intracellular killing of MD-2 opsonized gram-negative bacteria depend on TLR4 signaling.

Authors:  Vishal Jain; Annett Halle; Kristen A Halmen; Egil Lien; Marie Charrel-Dennis; Sanjay Ram; Douglas T Golenbock; Alberto Visintin
Journal:  Blood       Date:  2008-01-18       Impact factor: 22.113

4.  Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching.

Authors:  Hilde-Kari Guttormsen; Lawrence C Paoletti; Keith G Mansfield; Wojcieck Jachymek; Harold J Jennings; Dennis L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-31       Impact factor: 11.205

5.  Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells.

Authors:  Hilde-Kari Guttormsen; Yongdong Liu; Lawrence C Paoletti
Journal:  Hum Vaccin       Date:  2008-10-01

Review 6.  Protection Against Invasive Infections in Children Caused by Encapsulated Bacteria.

Authors:  Manish Sadarangani
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

7.  Novel Multiplex Immunoassays for Quantification of IgG against Group B Streptococcus Capsular Polysaccharides in Human Sera.

Authors:  Giada Buffi; Bruno Galletti; Maria Stella; Daniela Proietti; Evita Balducci; Maria Rosaria Romano; Elena Mori; Monica Fabbrini; Marzia Monica Giuliani; Francesco Berti; Immaculada Margarit
Journal:  mSphere       Date:  2019-08-07       Impact factor: 4.389

Review 8.  A Vaccine Against Group B Streptococcus: Recent Advances.

Authors:  Clara Carreras-Abad; Laxmee Ramkhelawon; Paul T Heath; Kirsty Le Doare
Journal:  Infect Drug Resist       Date:  2020-04-29       Impact factor: 4.003

9.  Aetiology of neonatal sepsis in Nigeria, and relevance of Group b streptococcus: A systematic review.

Authors:  Nubwa Medugu; Kenneth Iregbu; Pui-Ying Iroh Tam; Stephen Obaro
Journal:  PLoS One       Date:  2018-07-17       Impact factor: 3.240

10.  Progress toward a group B streptococcal vaccine.

Authors:  Joon Young Song; Jae Hyang Lim; Sangyong Lim; Zhi Yong; Ho Seong Seo
Journal:  Hum Vaccin Immunother       Date:  2018-07-16       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.